The novel IDO-1 inhibitor 3-047 combined with icaritin ameliorates neuroinflammation and diabetes-associated cognitive dysfunction with suppression of TLR4/MyD88/NF-κB signaling.

However, after 16 weeks of co-administration of the drugs, blood glucose of mice was significantly reduced ( p < 0.01, p < 0.05), and blood glucose of the Met group showed a significant trend of reduction ( p < 0.001) ( Figure 1C ); the administration did not affect the body weight of db/db mice ( Figure 1D ).

also in 9,775 other papers

Although the increase in mitochondrial area did not reach statistical significance, a clear recovery trend was observed ( Figures 4A, C, D ).

also in 111,027 other papers

db/db mice showed a significant increase in fasting blood glucose compared to db/m mice ( p < 0.01), and blood glucose was significantly improved after drug administration ( p < 0.01, p < 0.05) ( Figure 1E ), but there was no significant difference in insulin levels ( Figure 1F ), and the HOMA-IR showed a trend of difference identical to that of the fasting blood glucose with the same trend of difference ( Figure 1G ).

also in 53,322 other papers